PAREXEL Ranks Fifth in The Boston Globe’s Annual “Globe 100” List of Massachusetts’ Best Performing Public CompaniesCompany Named to Globe 100 for Fifth Consecutive Year
Boston, MA, U.S., May 30, 2013 -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has been named to the Boston Globe’s 25th annual “Globe 100” list of best performing public companies in Massachusetts. PAREXEL was ranked fifth overall, up significantly from the previous year.
The Globe 100 ranks the best-performing publicly traded corporations based in Massachusetts by how well they performed on a number of metrics, including sales, profits, and returns for shareholders during 2012. To qualify for the Globe 100, a Massachusetts-based company must have been publicly traded for the entire 2012 calendar year and must have reported a positive net income for both 2011 and 2012.
“We are pleased to be ranked fifth overall within the Globe 100,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. “This recognition not only demonstrates that our services are helping biopharmaceutical organizations transform drug development, but also reflects our enduring commitment to being a leading and innovative Massachusetts-based organization.”
The company has an extensive track record of driving innovation in the biopharmaceutical services industry. Under von Rickenbach’s leadership, the PAREXEL Academy, a leading provider of education and professional training for the biopharmaceutical industry in the field of clinical research, is committed to developing the next generation of clinical research professionals in the Bay State. That commitment is evident in programs like PAREXEL’s new partnership with Salem State University to offer a Post Graduate Certificate Program in Clinical Trial Management. Most recently, von Rickenbach was honored for his commitment and contributions to the biotechnology industry as the 2013 recipient of the Henri Termeer Innovative Leadership Award presented by the Massachusetts Biotechnology Council.
PAREXEL has over 14,300 employees in 78 offices across 52 countries. In Massachusetts, the company employs 2,000 people in two locations, including its corporate headquarters in Waltham.
“As it always has, the Globe 100 list reflects the dynamic nature of business not only in Massachusetts but also the world,” said Steve Syre, Boston Globe business columnist and editor of the 2013 Globe 100 Magazine. “Several companies on this year’s list did not even exist when it debuted in 1989. In fact it’s quite possible those companies employ people who weren’t even born in 1989.”
The annual ranking of companies appeared in a magazine published in the Boston Sunday Globe on May 19 and can be seen at BostonGlobe.com/globe100.
# # #
About the Globe 100 ranking methodology
The Globe 100 ranks Massachusetts-based public companies based on financial data from the four quarters ending December 31, 2012. To be eligible, the company must be traded publicly for the entire 2012 calendar year on the New York Stock Exchange, the Nasdaq or the American Stock Exchange and report revenue and profit for both 2011 and 2012. Companies are ranked on four criteria: return on average equity, one-year percentage change in revenue, one-year percentage change in profit margin and 2012 revenue.
About The Boston Globe
The Boston Globe is wholly owned by the New York Times Company, a leading global, multimedia news and information company with 2012 revenues of $2.0 billion, includes The New York Times, the International Herald Tribune, The Boston Globe, NYTimes.com, BostonGlobe.com, Boston.com and related properties. The Company’s core purpose is to enhance society by creating, collecting and distributing high-quality news and information.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 78 locations throughout 52 countries around the world, and has approximately 14,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 as filed with the SEC on May 6, 2013, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.